Get started
BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

BCRX trade ideas

$BCRX Volume spike on Friday , lets hope history repeats BCRX's berotralstat (BCX7353) is an orally active bradykinin inhibitor currently under review in Japan, the U.S., and Europe for the treatment of hereditary angioedema (HAE). BCRX anticipates two regulatory approvals for berotralstat in 2020, and one early in 2021. Even more impressive, however, is that BCRX will likely get a significant near-term boost from the success of GILD's remdesivir in the treatment of COVID-19. First results from phase 3 studies of remdesivir in China in mild-moderate and severe COVID-19 are imminent. Results from similar studies in the U.S. should follow within a month. BCRX will then likely experience even greater interest in its RNA replicase inhibitor, galidesivir. That is, remdesivir results will likely trigger a massive surge in BCRX stock price. Source seekignaplha
NASDAQ:BCRXLong
by Bullishcharts
1
Only one way for Biocryst to go from here!Biocryst has fallen out of its wedge a couple of days ago. Since then, it has hit bottom resistance of $2.56. There is strong support there as we can see in late 2019, it held up the stock. It may make the same move as then where it hits $3.20. It will come at it with more force though and potentially break it. First, it has to break the first resistance at $2.76. It will likely take 2 tries and on the second one it will probably head straight to the $3.20. If you find my ideas helpful, please give me a like and a follow. Thanks!
NASDAQ:BCRXLong
by anand_swamy
BCRX 1D POSSIBLE LONGNow for something different. Fundumentally the general fear of the virus is the only reason I see this going up.The question is if up how much up? 3 scenarios either : 1.this goes to 4$ wicth is a very strong level both as mirror and a correction from the previous gap down (fibbo) 2.this explodes up to 6.8-6.9 to fill the gap then most likely crashes to 4 levels. 3.This goes down again like my AKORN review which technically looks annoyingly familiar.The fundumentals are the key here though. So I will choose scenario 2 cause of the ridicoulous R/R .It does not fit my general strategy still I would like to see how this plays out with a smaller R than usual.
NASDAQ:BCRXLong
by MarketSeaman
BioCryst Pharmaceuticals, Inc. The rush is on for a vaccine to combat coronaviruse, Bio Crystal Pharma is one of the companies tipped to be in the running to fight the disease. BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
NASDAQ:BCRXLong
by Bullishcharts
BIOCRYST PHARMACEUTICALS INC. - BCRX Shaping-Up After breaking ‘top-side’ two (2) weeks ago, shares of BioCryst Pharmaceuticals Inc. (BCRX) continue to digest and consolidate the recent run into higher ground in a constructive manner. As we can observe from the Daily chart above, BCRX appears to be building-out a Flag pattern that both investors/traders may want to monitor in the days/weeks ahead. Nonetheless, the action remains technically favorable, whereby BCRX finds itself in a decent posture and readers may want to put BCRX front-and-center on their radars for further monitoring.
NASDAQ:BCRX
by CryptoPulses